RxDoctor Payments Data

Deepakraj Gajanana, MD

Interventional Cardiology · Elmira, NYNPI 1457527962

Payments from drug & device makers

$5,671in general payments, 2019–2025

Across 120 payments — averaging $47.26 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Abbott$2K
  • Boston Scientific$790
  • Medtronic$595
  • AstraZeneca$359
  • Recor Medical Inc$318
  • Shockwave Medical, Inc$295
  • plus $2K from 18 others

What the payments were for

  • Travel & lodging$92316%
  • Food & beverage$4,64582%
  • Education$1032%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$5,671 in reported general payments places this provider in the 35th percentile of 382 interventional cardiology providers in New York.

See all interventional cardiology providers in New York

Medicare billing

Part B allowed, 2024
$52,547
Medicare patients
160
Services billed
363

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EntrestoSacubitril/Valsartan16$22,803
EliquisApixaban14$21,400
BrilintaTicagrelor28$16,685
Isosorbide Mononitrate ErIsosorbide Mononitrate83$984
Metoprolol Succinate62$609
Atorvastatin Calcium77$599
Losartan Potassium53$557
ClopidogrelClopidogrel Bisulfate80$435
Ezetimibe21$358
Amlodipine Besylate75$324
Carvedilol28$172
Spironolactone16$165
Hydralazine Hcl11$139
Metoprolol Tartrate28$129
Lisinopril56$125

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
NovartisEntresto$97$22,80316 claims
PfizerEliquis$17$21,40014 claims
AstraZenecaBrilinta$359$16,68528 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 35th percentile of 382 interventional cardiology providers in New York.

Other interventional cardiology in Elmira

See the full list for New York

Where these figures come from

Is this you, or does something look wrong? →